In vitro Toxicity of Rivastigmine and Donepezil in Cells of Epithelial Origin

Neurospecific acetylcholinesterase inhibitors have been shown to lower intraocular pressure (IOP) in normal rabbits and might have additional neuroprotective effects. This study was set out to explore and compare the toxicity of two selective acetylcholinesterase inhibitors, rivastigmine and donepezil, on two standardized cell lines of epithelial origin. Chang and Vero cells were incubated with various concentrations of rivastigmine or donepezil. Acute toxicity (4 h) was assessed by monitoring the permeability of cells to propidium iodide. Chronic toxicity (7 days) was determined by monitoring the effect of the two drugs on esterase activity and cell proliferation. The viability of cells was also assessed morphologically by microscopic inspection. Signs of acute toxicity became manifest at a rivastigmine concentration of 50 mg/ml in both Chang and Vero cells. Indications of chronic toxicity became obvious at concentrations of as low as 1 × 10–5 mg/ml. In contrast, degenerative morphological changes became manifest only at a concentration of as high as 1 mg/ml. In donepezil-treated cells, acute toxicity was not observed in the concentration range tested, whereas chronic toxicity was detected at 1 × 10–1 mg/ml in both Chang and Vero cells, a concentration at which degenerative morphological changes became evident as well. In contrast to rivastigmine, donepezil elicited no signs of acute or chronic toxicity in either Chang or Vero cells at the IOP-lowering concentration of 1 × 10–4 mg/ml. At this dose, the drug is therefore unlikely to evoke deleterious effects on ocular surface tissues in the clinical setting.

[1]  H. Mietz,et al.  The effect of preservatives and antiglaucomatous medication on the histopathology of the conjunctiva , 1994, Graefe's Archive for Clinical and Experimental Ophthalmology.

[2]  U. Kristen,et al.  In vitro cytotoxicity testing for prediction of acute human toxicity , 1994, Cell Biology and Toxicology.

[3]  A. Vaheri,et al.  Histochemical study of alkali-burned rabbit anterior eye segment in which severe lesions were prevented by aprotinin treatment , 2004, Histochemistry.

[4]  D. Goldblum,et al.  Topical rivastigmine, a selective acetylcholinesterase inhibitor, lowers intraocular pressure in rabbits. , 2000, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[5]  A. C. Ventura,et al.  Toxicity of pentoxifylline on monolayers of highly proliferative cells of epithelial origin. , 1999, Journal of Ocular Pharmacology and Therapeutics.

[6]  M. Boehnke,et al.  Influences of methylcellulose on corneal epithelial wound healing. , 1999, Journal of Ocular Pharmacology and Therapeutics.

[7]  C. Baudouin,et al.  Toxicity of preserved and unpreserved antiglaucoma topical drugs in an in vitro model of conjunctival cells. , 1999, Current Eye Research.

[8]  R. Polinsky,et al.  Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. , 1998, Clinical therapeutics.

[9]  A. Nordberg,et al.  Tacrine and donepezil attenuate the neurotoxic effect of Aβ(25‐35) in rat PC12 cells , 1998, Neuroreport.

[10]  S. Constantini,et al.  Rivastigmine, a brain-selective acetylcholinesterase inhibitor, ameliorates cognitive and motor deficits induced by closed-head injury in the mouse. , 1998, Journal of neurotrauma.

[11]  E. Shohami,et al.  Cerebro-protective effects of ENA713, a novel acetylcholinesterase inhibitor, in closed head injury in the rat , 1998, Brain Research.

[12]  S. Lichtman,et al.  Donepezil medicated memory improvement in traumatic brain injury during post acute rehabilitation. , 1998, Brain injury.

[13]  M. Cottin,et al.  Fluorescein leakage test: a useful tool in ocular safety assessment. , 1997, Toxicology in vitro : an international journal published in association with BIBRA.

[14]  J. Vickers The cellular mechanism underlying neuronal degeneration in glaucoma: parallels with Alzheimer's disease. , 1997, Australian and New Zealand journal of ophthalmology.

[15]  A. Enz,et al.  Cholinesterase Inhibitors: An Overview of their Mechanisms of Action , 1997 .

[16]  H. Sugimoto,et al.  Synthesis and structure-activity relationships of acetylcholinesterase inhibitors: 1-benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine hydrochloride and related compounds. , 1995, Journal of medicinal chemistry.

[17]  J. Zieske,et al.  Effect of epidermal growth factor, hepatocyte growth factor, and keratinocyte growth factor, on proliferation, motility and differentiation of human corneal epithelial cells. , 1994, Experimental eye research.

[18]  W. Puhl,et al.  [In vitro toxicity tests of bioceramics and bone transplants in fibroblast culture]. , 1993, Biomedizinische Technik. Biomedical engineering.

[19]  R. Hitchings,et al.  Adverse effects of topical antiglaucomatous medications on the conjunctiva. , 1993, The British journal of ophthalmology.

[20]  J. Jonas,et al.  Human optic nerve fiber count and optic disc size. , 1992, Investigative ophthalmology & visual science.

[21]  R. Tripathi,et al.  Cytotoxicity of ophthalmic preservatives on human corneal epithelium. , 1992, Lens and eye toxicity research.

[22]  R. Ritch,et al.  Optic nerve head and nerve fiber layer in Alzheimer's disease. , 1991, Archives of ophthalmology.

[23]  Y. Yamanishi,et al.  E2020 - THE PHARMACOLOGY OF A PIPERIDINE CHOLINESTERASE INHIBITOR , 1991 .

[24]  M. Giasson,et al.  Topical fibronectin and aprotinin for keratectomy wound healing in rabbits. , 1990, Archives of ophthalmology.

[25]  D. G. Wenzel,et al.  A quantitative metabolic inhibition test for screening toxic compounds with cultured cells. , 1983, Toxicology.

[26]  J. Massoulie,et al.  The molecular forms of cholinesterase and acetylcholinesterase in vertebrates. , 1982, Annual review of neuroscience.

[27]  I. B. Wilson,et al.  Multiple forms of acetylcholinesterase from the ciliary body of the human eye. , 1974, Experimental eye research.

[28]  T. Mittag,et al.  Properties of cholinesterases of human ocular tissues. , 1972, Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde.

[29]  I. Leopold,et al.  Cholinesterase isoenzymes in human ocular tissue homogenates. , 1971, American journal of ophthalmology.

[30]  Kronfeld Pc Eserine and pilocarpine: our 100-year-old allies. , 1970 .

[31]  P. Kronfeld Eserine and pilocarpine: our 100-year-old allies. , 1970, Survey of ophthalmology.

[32]  A. D. Roetth Lens Opacities in Glaucoma Patients on Phospholine Iodide Therapy , 1966 .

[33]  C. Mcculloch,et al.  The effect of echothiophate iodide on systemic cholinesterase. , 1966, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.

[34]  A. D. De Roetth Lens opacities in glaucoma patients on phospholine iodide therapy. , 1966, American journal of ophthalmology-glaucoma.

[35]  John H. Draize,et al.  METHODS FOR THE STUDY OF IRRITATION AND TOXICITY OF SUBSTANCES APPLIED TOPICALLY TO THE SKIN AND MUCOUS MEMBRANES , 1944 .